Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 3 studies | 16% ± 1% |
Insufficient scRNA-seq data for expression of EPOR at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 3290.96 | 258 / 258 | 100% | 36.68 | 230 / 230 |
thymus | 100% | 11804.12 | 653 / 653 | 99% | 61.70 | 596 / 605 |
kidney | 100% | 4716.52 | 89 / 89 | 96% | 14.89 | 861 / 901 |
pancreas | 100% | 1451.60 | 328 / 328 | 93% | 11.17 | 166 / 178 |
brain | 94% | 524.44 | 2476 / 2642 | 97% | 9.91 | 687 / 705 |
prostate | 99% | 1290.55 | 243 / 245 | 92% | 7.61 | 461 / 502 |
ovary | 98% | 621.69 | 177 / 180 | 92% | 20.45 | 397 / 430 |
breast | 100% | 1319.94 | 459 / 459 | 79% | 7.61 | 886 / 1118 |
lung | 100% | 1754.56 | 578 / 578 | 73% | 8.97 | 843 / 1155 |
skin | 69% | 309.46 | 1254 / 1809 | 99% | 16.48 | 467 / 472 |
liver | 100% | 1293.46 | 226 / 226 | 68% | 6.38 | 275 / 406 |
uterus | 99% | 1068.59 | 169 / 170 | 67% | 10.11 | 306 / 459 |
bladder | 100% | 759.90 | 21 / 21 | 65% | 7.08 | 326 / 504 |
stomach | 96% | 1307.08 | 345 / 359 | 40% | 2.63 | 114 / 286 |
intestine | 90% | 482.72 | 865 / 966 | 42% | 3.31 | 219 / 527 |
esophagus | 71% | 347.17 | 1022 / 1445 | 42% | 3.15 | 77 / 183 |
spleen | 100% | 2725.27 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 1386.85 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1218.91 | 1332 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 1256.26 | 858 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 14.30 | 79 / 80 |
peripheral blood | 98% | 697.48 | 912 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 83% | 5.20 | 24 / 29 |
muscle | 58% | 240.92 | 464 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 53% | 3.80 | 24 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007165 | Biological process | signal transduction |
GO_0007420 | Biological process | brain development |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0019221 | Biological process | cytokine-mediated signaling pathway |
GO_0038162 | Biological process | erythropoietin-mediated signaling pathway |
GO_0030097 | Biological process | hemopoiesis |
GO_0046697 | Biological process | decidualization |
GO_0007507 | Biological process | heart development |
GO_0016607 | Cellular component | nuclear speck |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0004900 | Molecular function | erythropoietin receptor activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | EPOR |
Protein name | Truncated EPOR Erythropoietin receptor Erythropoietin receptor (EPO-R) Truncated erythropoietin receptor |
Synonyms | |
Description | FUNCTION: Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.; FUNCTION: Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling. |
Accessions | ENST00000222139.11 [P19235-1] I6RPE1 A9QVL7 ENST00000588859.5 A0A6G6CDE1 A0A6G6CDF3 ENST00000592375.6 [P19235-3] A0A6G6CDE0 ENST00000586890.5 A0A6G6CDG4 A0A6G6CDD6 A0A6G6CDD9 ENST00000591958.5 P19235 I6R7G3 A0A6G6CDC9 K7EN47 K7ERB5 A0A6G6CDG2 K7EP50 |